EP 2916868 B1 20220511 - PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR
Title (en)
PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR
Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT EINEM PDE4-HEMMER UND EINEM PI3-DELTA- ODER EINEM DUALEN PI3-DELTA-GAMMA-KINASEHEMMER
Title (fr)
COMPOSITIONS PHARMACEUTIQUES CONTENANT UN INHIBITEUR DE PDE4 ET UN INHIBITEUR DE PI3 KINASE DELTA OU UN DOUBLE INHIBITEUR DE PI3 KINASE DELTA ET GAMMA
Publication
Application
Priority
- IN 2762CH2012 A 20121108
- IN 4688CH2012 A 20121108
- IB 2013059983 W 20131107
Abstract (en)
[origin: US2015272936A1] This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, COPD). The method comprises administering a PI3K Delta inhibitor or a dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor. The present invention also relates to pharmaceutical compositions containing a PI3K Delta or dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor.
IPC 8 full level
A61K 31/44 (2006.01); A61K 31/4035 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61P 11/00 (2006.01); A61P 11/06 (2006.01)
CPC (source: EA EP KR US)
A61K 31/353 (2013.01 - KR); A61K 31/44 (2013.01 - EA EP KR US); A61K 31/47 (2013.01 - KR); A61K 31/519 (2013.01 - EA EP US); A61K 31/52 (2013.01 - EA EP KR US); A61K 45/06 (2013.01 - EA EP KR US); A61P 1/04 (2017.12 - EA EP); A61P 1/16 (2017.12 - EA EP); A61P 3/10 (2017.12 - EA EP); A61P 7/06 (2017.12 - EA EP); A61P 9/00 (2017.12 - EA EP); A61P 11/00 (2017.12 - EA EP); A61P 11/02 (2017.12 - EA EP); A61P 11/06 (2017.12 - EA EP); A61P 11/08 (2017.12 - EA EP); A61P 13/10 (2017.12 - EA EP); A61P 13/12 (2017.12 - EA EP); A61P 15/02 (2017.12 - EA EP); A61P 17/00 (2017.12 - EA EP); A61P 17/04 (2017.12 - EA EP); A61P 17/06 (2017.12 - EA EP); A61P 19/02 (2017.12 - EA EP); A61P 19/10 (2017.12 - EA EP); A61P 21/00 (2017.12 - EA EP); A61P 21/04 (2017.12 - EA EP); A61P 25/00 (2017.12 - EA EP); A61P 27/14 (2017.12 - EA EP); A61P 29/00 (2017.12 - EA EP); A61P 37/02 (2017.12 - EA EP); A61P 37/06 (2017.12 - EA EP); A61P 37/08 (2017.12 - EA EP); A61P 43/00 (2017.12 - EA EP); A61K 2300/00 (2013.01 - EA US)
C-Set (source: EP US)
Citation (examination)
- EDWARD BANHAM-HALL ET AL: "The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases", THE OPEN RHEUMATOLOGY JOURNAL 2010, vol. 6, no. 1, 7 September 2012 (2012-09-07), pages 245 - 258, XP055618165, ISSN: 1874-3129, DOI: 10.2174/1874312901206010245
- VAN SCHALKWYK ET AL: "Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 116, no. 2, 1 August 2005 (2005-08-01), pages 292 - 298, XP005002812, ISSN: 0091-6749
- HATZELMANN A ET AL: "ANTI-INFLAMMATORY AND IMMUNOMODULATORY POTENTIAL OF THE NOVEL PDE4 INHIBITOR ROFLUMILAST IN VITRO", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 297, no. 1, 1 January 2001 (2001-01-01), pages 267 - 279, XP001024814, ISSN: 0022-3565
- ANDREAS EISENREICH ET AL: "PI3K Inhibitors in Cardiovascular Disease", CARDIOVASCULAR THERAPEUTICS, vol. 29, no. 1, 17 February 2011 (2011-02-17), pages 29 - 36, XP055063035, ISSN: 1755-5914, DOI: 10.1111/j.1755-5922.2010.00206.x
- SCHETT GEORG ET AL: "Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, 1 October 2010 (2010-10-01), XP002742266, DOI: 10.1177/1759720X10381432
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
US 2015272936 A1 20151001; US 9737521 B2 20170822; CA 2889905 A1 20140515; CN 104870017 A 20150826; CN 104870017 B 20200814; CN 111904962 A 20201110; EA 035391 B1 20200605; EA 201590721 A1 20150930; EP 2916868 A1 20150916; EP 2916868 B1 20220511; HK 1214159 A1 20160722; JP 2015536973 A 20151224; JP 2018203760 A 20181227; JP 6434416 B2 20181205; JP 7030656 B2 20220307; KR 20150079745 A 20150708; KR 20210010958 A 20210128; US 10058539 B2 20180828; US 10413532 B2 20190917; US 11065236 B2 20210720; US 2017319558 A1 20171109; US 2019083475 A1 20190321; US 2020237735 A1 20200730; WO 2014072937 A1 20140515
DOCDB simple family (application)
US 201314441758 A 20131107; CA 2889905 A 20131107; CN 201380063816 A 20131107; CN 202010719781 A 20131107; EA 201590721 A 20131107; EP 13795866 A 20131107; HK 16102228 A 20160226; IB 2013059983 W 20131107; JP 2015541279 A 20131107; JP 2018160208 A 20180829; KR 20157013518 A 20131107; KR 20217001956 A 20131107; US 201715654181 A 20170719; US 201816013607 A 20180620; US 201916557025 A 20190830